TABLE 2.
Baseline characteristics of study populationa
| Characteristic | Value for arm:
|
||
|---|---|---|---|
| A | B | C | |
| Dose regimen (mg/kg) | 10 | 10, 6 | 25 |
| n | 9 | 10 | 3 |
| Mean age (min, max) (yr) | 39 (24, 60) | 42 (22, 52) | 41 (36, 43) |
| Gender (%) | |||
| Male | 8 (89) | 9 (90) | 2 (67) |
| Female | 1 (11) | 1 (10) | 1 (33) |
| Race | |||
| White | 7 (78) | 8 (80) | 2 (67) |
| Black | 1 (11) | 0 (0) | 1 (33) |
| Hispanic | 1 (11) | 2 (20) | 0 (0) |
| Mean wt (min, max) (kg) | 80 (60, 100) | 75 (65, 87) | 69 (58, 80) |
| Median CD4+ T-cell count/mm3 (min, max) | 294 (89, 462) | 327 (109, 458) | 338 (274, 417) |
| Median baseline HIV-1 RNA (log10 copies/ml) (range) | 4.7 (3.8-5.7) | 4.7 (3.8-5.6) | 4.9 (4.2-5.7) |
a
Patients not taking antiretrovirals at baseline remained off background therapy during the study. Patients taking a failing regimen at baseline continued the failing regimen during the study.